Anti-Parkinson's Drugs: Global Markets to 2022

Published - Apr 2018| Analyst - BCC Research Reference Staff| Code - PHM193A
Anti-Parkinson's Drugs: Global Markets to 2022
Single User License: $5,500 Available in Member Preview now. Available to the general public
20 March 2018

Report Highlights

The global anti-Parkinson’s drugs market should reach $5.7 billion by 2022 from $4.2 billion in 2017 at a compound annual growth rate (CAGR) of 6.1% from 2017 to 2022.

Report Includes

  • 95 data tables
  • An overview of the global market for anti-Parkinson’s drugs and their future demand
  • Analyses of global market trends, with data from 2013-2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Analyses of the major factors and technological advances such as biomarkers, 3D printed drugs, mobile applications and wearable technologies in the monitoring and treatment of Parkinson’s disease
  • Discussion of the major segments of the anti-Parkinson’s drugs, i.e., dopaminergic drugs, dopamine agonists, enzyme inhibitors and other anti-Parkinson’s medications
  • Company profiles of the major players in the market, including AbbVie, Mylan Laboratories, Valeant Pharmaceuticals and Novartis

Report Scope 

This research report categorizes the anti-Parkinson’s drugs market by type. Product types include low dopaminergic, dopamine agonists, enzyme inhibitors and other anti-Parkinson’s medications.

Analyst Credentials

Led by head researcher Karthik Arun, BCC Research analysts craft Reference Reports with a unique end noted referencing methodology, which allows users to cross reference and trace market numbers back to their source. These individuals are experts in secondary research and primary forecasting - compiling and layering existing data with their original research and analysis. The team has decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Note: Reports are discounted or included with certain Memberships. See Membership Options.
Share This Report